XFORHealthcare · BiotechnologyThe 5 Wall Street analysts covering X4 Pharmaceuticals, Inc. hold a median 12-month price target of $12 — +330.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 58 of 100 as at 8 Oct 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores X4 Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (90): Analysts have, on balance, been raising their forecasts.
Volatility (28): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on XFOR, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +330.1% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 10 July 2026 | Wells Fargo | Initiates | Overweight | $11 |
| 2 June 2026 | Leerink Partners | Initiates | Outperform | — |
| 9 Mar 2026 | Guggenheim | Initiates | Buy | — |
| 5 Dec 2025 | Stifel | Maintains | Buy | — |
| 10 Nov 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 29 Aug 2025 | Stifel | Maintains | Buy | — |
| 13 Aug 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 2 May 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 27 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 26 Mar 2025 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 7 Feb 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 14 Jan 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 14 Nov 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 14 Nov 2024 | Stifel | Maintains | Buy | — |
| 28 June 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 31 May 2024 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 30 Apr 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 22 Mar 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 12 Dec 2023 | B. Riley Securities | Downgrade | Neutral | — |
| 11 Aug 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. XFOR appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 8 Oct 2026, X4 Pharmaceuticals, Inc. returned −16.0% against +16.2% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 5% of US stocks
Cheaper than 10% of US stocks
Cheaper than 49% of US stocks
Cheaper than 72% of US stocks
Higher than 97% of US stocks
Higher than 92% of US stocks
Higher than 11% of US stocks
Higher than 99% of US stocks
Higher than 12% of US stocks
Higher than 15% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
X4 Pharmaceuticals, Inc. has a market value of $274.6M and an enterprise value of $143.9M.
Revenue in the twelve months to 30 June 2026: $15.8M. The latest quarter grew 346.3% year on year.
Net income over the same four quarters: −$90.1M, a −568.8% net margin.
Free cash flow in the twelve months to 30 June 2026: −$88.7M.
Trailing P/E: 138.5×; forward P/E: −3.6× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
X4 Pharmaceuticals, Inc. employs 45 people — $352K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
| Company | Market cap | TKN rank |
|---|---|---|
| XFORX4 Pharmaceuticals, Inc. | $274.6M | 58 |
| BBOTBridgebio Oncology Therapeutics, Inc. | $274.2M | 7 |
| ABEOAbeona Therapeutics, Inc. | $283.0M | 40 |
| RCKTRocket Pharmaceuticals, Inc. | $284.6M | 58 |
| LRMRLarimar Therapeutics, Inc. | $285.1M | 29 |
| VNDAVanda Pharmaceuticals, Inc. | $267.8M | 47 |
| FULCFulcrum Therapeutics, Inc. | $286.1M | 38 |
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own X4 Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
X4 Pharmaceuticals announced it will host a virtual Investor Day on Thursday, October 29, 2026, from 10:00 a.m. to 12:00 p.m. ET, featuring key opinion leaders.
Why it matters — The event gives XFOR watchers a scheduled opportunity to hear company and key opinion leader presentations about the company focused on rare hematology diseases.
X4 Pharmaceuticals entered into a senior secured term loan facility of up to $150 million with K2 HealthVentures, replacing its prior loan agreement. The company also expects to complete enrollment in the Phase 3 4WARD trial by year-end 2026, with topline data in the first half of 2028.
Why it matters — The new facility provides access to funding for corporate and commercial activities, while the stated trial timeline gives XFOR watchers an update on the 4WARD program.
X4 Pharmaceuticals announced that, effective September 30, 2026, it issued inducement awards to new employees under its 2019 Inducement Equity Incentive Plan. The awards consist of options to purchase an aggregate of 80,000 shares of common stock, granted under Nasdaq Listing Rule 5635(c)(4) and approved by the Compensation Committee.
Why it matters — The news signals a potential increase in outstanding shares as X4 recruits new employees through equity-based inducement grants, which XFOR watchers may monitor for dilution and hiring activity.
Zacks reports that X4 Pharmaceuticals (XFOR) shares have fallen 25.4% over the past four weeks, leaving the stock technically oversold, which suggests heavy selling pressure has been exhausted. The article notes that strong agreement among Wall Street analysts in revising earnings estimates higher points to a potential near-term trend reversal.
Why it matters — XFOR watchers would care because the piece highlights oversold conditions and upward analyst estimate revisions as signals of a possible turnaround for the stock.
X4 Pharmaceuticals (XFOR) fell 20.8% over four weeks and is now technically in oversold territory, suggesting heavy selling pressure may have been exhausted. The report notes that further agreement among Wall Street analysts in raising earnings estimates could signal a trend reversal for the stock.
Why it matters — XFOR watchers would care because oversold technical conditions combined with upward analyst earnings estimate revisions may indicate the stock's recent decline could be reversing.
The 5 Wall Street analysts covering X4 Pharmaceuticals, Inc. have a median 12-month price target of $12, with estimates ranging from $10 to $13. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 5 analysts covering X4 Pharmaceuticals, Inc., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks X4 Pharmaceuticals, Inc. 58 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 8 Oct 2026, X4 Pharmaceuticals, Inc. ranks 58 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (90 of 100).
No one can know that. What the data says: the median 12-month target from 5 analysts implies +330.1% from the last close, and Ticker Nerd's factor model ranks X4 Pharmaceuticals, Inc. 58 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering X4 Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for XFOR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $13 over the next 12 months.
X4 Pharmaceuticals, Inc. returned -16.0% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
X4 Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare diseases of the immune system and rare hematology disorders.
The most recent item we track (GlobeNewsWire, 9 Oct 2026): "X4 Pharmaceuticals to Host Virtual Investor Day on Thursday, October 29, 2026, Featuring Key Opinion Leaders". X4 Pharmaceuticals announced it will host a virtual Investor Day on Thursday, October 29, 2026, from 10:00 a.m. to 12:00 p.m. ET, featuring key opinion leaders.
X4 Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare diseases of the immune system and rare hematology disorders. The company’s core work centers on CXCR4-targeted medicines, including mavorixafor, an oral small-molecule antagonist designed to improve immune cell trafficking and address conditions marked by chronic neutropenia and immunodeficiency. X4 Pharmaceuticals markets XOLREMDI in the United States and continues to evaluate mavorixafor in additional indications through clinical development programs. Its portfolio and commercial activity place it at the intersection of immunology, hematology, and rare-disease care, serving patients with significant unmet medical needs. Based in Boston, Massachusetts, X4 Pharmaceuticals plays a specialized role in the biotechnology market by focusing on treatments for underserved patient populations.
CEO Dr. Paula Ragan Ph.D. · 45 employees · United States · https://www.x4pharma.com
